A similar rationale may be employed for comparison of MEK/AKT-inhibitor and LY3009120/AKT-inhibitor combinations in KRASmut/PIK3CAWT CRC models, with potentially similar outcomes to the PI3K combinations. This evidence concerns the gene AKT1 and colorectal carcinoma.